PALI PALISADE BIO, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1357459 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-289.2%
TTM EPS YoY144.4%
Revenue 3-yr CAGR-98.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-9,625,400,000.0%
Net margin-8,739,200,000.0%
FCF margin—
EBITDA margin-9,625,400,000.0%
Returns
ROE-75.6%
ROA-69.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets5.1%
Debt / equity0.00x
Current ratio20.16x
Interest coverage-16,042.33x
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $12.00M | $6.00M | $6.00M | $6.17M | $1.39M | $1.68M | $950,000 | $0 |
| SG&A expense | $5.12M | $4.80M | $4.35M | $3.81M | $1.53M | $1.17M | $1.36M | $1.30M |
| Operating income | -$15.70M | -$11.70M | -$10.75M | -$9.98M | -$2.92M | -$2.84M | -$2.31M | -$3.38M |
| Interest expense | $0 | $0 | $1,000 | $2,000 | $5,000 | $2,000 | $1,000 | $3,000 |
| Net income | -$14.62M | -$10.57M | -$9.60M | -$8.90M | -$2.87M | -$2.78M | -$2.23M | -$3.34M |
| EBITDA | -$15.70M | -$11.70M | -$10.75M | -$9.98M | -$2.92M | -$2.84M | -$2.31M | -$3.38M |
| EPS (basic) | -0.07 | -0.05 | -0.05 | — | -0.38 | -0.58 | -0.47 | — |
| EPS (diluted) | -0.07 | -0.05 | -0.05 | — | -0.38 | -0.58 | -0.47 | — |
| Weighted avg. shares (diluted) | 212.03M | 211.38M | 209.66M | — | 7.47M | 4.80M | 4.80M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $113.61M | $125.17M | $132.63M | $133.38M | $5.23M | $5.42M | $7.23M | $9.82M |
| Receivables | — | $500,000 | — | $0 | — | $0 | — | $0 |
| Current assets | $117.47M | $127.26M | $133.24M | $134.22M | $6.83M | $6.45M | $7.89M | $10.49M |
| PP&E, net | — | — | — | $0 | $0 | $1,000 | $2,000 | $3,000 |
| Total assets | $118.55M | $127.31M | $133.31M | $134.34M | $6.97M | $6.67M | $8.19M | $10.88M |
| Current liabilities | $5.83M | $5.25M | $5.62M | $4.64M | $3.48M | $3.97M | $2.78M | $3.24M |
| Total liabilities | $6.11M | $5.57M | $5.95M | $4.96M | $3.76M | $4.05M | $2.86M | $3.39M |
| Shareholders' equity | $112.44M | $121.75M | $127.36M | $129.38M | $3.21M | $2.62M | $5.33M | $7.49M |
| Shares outstanding | 174.44M | 173.60M | 167.42M | 159.44M | 9.12M | 4.80M | 4.40M | 2.77M |
| Cash flow statement | ||||||||
| Operating cash flow | -$11.76M | -$7.60M | -$3.89M | -$3.14M | -$3.55M | -$1.82M | -$2.33M | -$2.38M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$2.38M |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $200,000 | $147,000 | $3.13M | $131.33M | $3.36M | $4,000 | -$258,000 | $4.16M |
| Depreciation & amortization | $0 | $0 | $0 | $0 | $1,000 | $1,000 | $1,000 | $0 |
| Stock-based compensation | $5.05M | $4.78M | $4.30M | $3.73M | $85,000 | $60,000 | $69,000 | $77,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.